Merck today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash.
- Continued investment in Exelead’s capabilities planned over the next ten years
- Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
- Company now offers comprehensive end-to-end services across mRNA value chain
Merck, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable Merck’s Life Science business sector to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. Merck plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
“With the addition of Exelead’s leading capabilities and highly experienced team, Merck achieves an important milestone in becoming one of the leading CDMO players in mRNA vaccines and therapeutics, offering an integrated CDMO across the mRNA value chain from pre-clinical to commercial,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “mRNA holds much promise as a treatment well beyond Covid-19 and we will further invest in this technology to help realize its potential.”
Exelead, a biopharmaceutical CDMO, specializes in PEGylated products and complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology, which is key in mRNA vaccines and therapeutics for use in Covid-19 and many other indications. The company has experience in all development phases from pre-clinical development to commercial contract manufacturing for LNP formulations, including fill and finish. Exelead will complement Merck’s more than 20 years’ experience in producing lipids as well as its mRNA manufacturing capabilities acquired through AmpTec in 2020. This integrated offering will accelerate Merck’s ability to bring life-enhancing vaccines and treatments to patients faster by simplifying supply chain complexity and enhancing speed to market through its end-to-end portfolio.
Over the past two years, Merck’s Life Science business sector has made significant investments to advance traditional and novel modalities (mAb, ADC, HP-API, viral vector, and mRNA) through acquisitions and expansions. The acquisition of Exelead is another milestone to accelerate innovation in Merck’s Process Solutions and Life Science Services businesses, one of the company’s three growth engines (“Big 3”), through targeted smaller to medium-sized acquisitions with high impact.